Abstract: A compressor assembly includes a first compressor, a second compressor, a first oil separator, a second oil separator, a storage container, a gas-liquid separator, a liquid balance pipe, and a gas balance pipe. The first compressor has a first air return port, and the second compressor has a second air return port. The first oil separator has a first oil outlet, the second oil separator has a second oil outlet, and the storage container has a refrigerant inlet, the first oil outlet and the second oil outlet both being in communication with the refrigerant inlet. The gas-liquid separator has a first gas separation outlet, a second gas separation outlet, a first oil return hole and a second oil return hole, the first gas separation outlet and the first oil return hole both being in communication with the first gas return port.

Abstract: Provided are a benzimidazole compound as represented by formula (I) or a salt thereof, a preparation method therefor, and the use thereof. The benzimidazole compound or the salt thereof has excellent insecticidal and acaricidal effects, and can display acaricidal effects especially when same is used at a low concentration.

Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I?: wherein the variables of Formula I? are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.

Abstract: The present disclosure provides a method and device for position determination, an air conditioning system, and a readable storage medium. The method for position determination includes: acquiring return air temperature information of each indoor unit; determining a first correlation coefficient between every two indoor units based on the return air temperature information; classifying indoor units based on the first correlation coefficient to obtain a number of classified groups; and generating relative position information in each classified group based on the first correlation coefficient by taking any one of the indoor units as a locating point. Maintenance personnel are not required to manually maintain a relative position relation of indoor units. Therefore, the maintenance difficulty of the relative position relation of indoor units is reduced, and a time cost and a labor cost required for maintenance are reduced accordingly.

Abstract: A seat slide device includes a pair of sliders each including a fixed rail, a movable rail slidably guided by the fixed rail, a bracket on the movable rail configured so that front and rear sides swing opposite to each other in a vertical direction with a longitudinal-intermediate part as a fulcrum, a support bracket supported on the bracket via a hinge and configured to rotate in only one direction from a predetermined orientation about an lateral-direction axis relative to the bracket, a movement-restricting portion configured to restrict sliding of the movable rail while a rear part of the bracket is raised and to release the restriction while the rear part of the bracket is lowered; and a towel bar connecting each support bracket. The hinge part prohibits a rotation of the support bracket while the towel bar is lifted and permits the rotation while the towel bar is lowered.

Abstract: A seat slide device includes a pair of sliders each including a fixed rail, a movable rail slidably guided by the fixed rail, a bracket on the movable rail configured so that front and rear sides swing opposite to each other in a vertical direction with a longitudinal-intermediate part as a fulcrum, a support bracket supported on the bracket via a hinge and configured to rotate in only one direction from a predetermined orientation about an lateral-direction axis relative to the bracket, a movement-restricting portion configured to restrict sliding of the movable rail while a rear part of the bracket is raised and to release the restriction while the rear part of the bracket is lowered; and a towel bar connecting each support bracket. The hinge part prohibits a rotation of the support bracket while the towel bar is lifted and permits the rotation while the towel bar is lowered.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: A mat mounting structure for mounting a mat on a seat back frame in a seat back may have a guide wire attachable to the mat configured to receive a force from a back of an occupant on the seat back. The guide wire may have a straight part extending linearly in a longitudinal direction of the seat back frame on a head side or a root side of the seat back frame. A bushing including a penetration hole in which the straight part is insertable in the longitudinal direction may be included in the structure. An attachment hole part in the seat back frame may also be part of the structure. The bushing may be detachably engageable with and attachable to the attachment hole part.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.